Meaningful research [9] estimates that the prevalence of postpartum preeclampsia ranges between 0.3% and 27.5% of all pregnancies in the United States. The antiangiogenic protein, soluble fms-like tyrosine kinase 1 (sFlt1), is elevated in pregnant women [10,11]. In the postpartum period, circulating inflammatory factors are no longer different between women with early preeclampsia and those with normal pregnancy at one to three years postpartum [12]. Here, FLT1 is linked to preeclampsia.